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ABSTRACT
Objectives To determine the incidence and
characteristics of randomised controlled trials that report
using the modified intention to treat approach, and how
the approach is described.
Design Systematic review.
DatasourcesPubMed,Embase,Cochranecentralregister
of controlled trials, ISI Web of Knowledge, Ovid, HighWire
Press, Science-Direct, Ingenta, Medscape, BioMed
Central, Springer, and Wiley, from inception to December
2006.
Main outcome measures Incidence of trials in which use
of modified intention to treat was reported, and how the
approach was described (classified according to the type
and number of deviations from the intention to treat
approach).
Results 475 randomised controlled trials reported use of
a modified intention to treat analysis. Of these, 76 (16%)
were published in five highly cited general medical
journals. The incidence of all trials that reported use of
modified intention to treat published in journals indexed
in Medline increased from 0.006% in 1982-6 to 0.5% in
2002-6(P<0.001forlineartrend).Whenthedescriptionof
themodifiedintentiontotreatwasexaminedineachtrial,
192 (40%) reported one type of deviation from the
intention to treat approach, 261 (55%) reported two or
moretypes,and22(5%)didnotdescribeanytype.In266
(56%) of the trials the deviation was related to the
treatment received, in 196 (41%) to a post-baseline
assessment, in 118 (25%) to a baseline assessment, in
108 (23%) to a target condition, and in 23 (5%) to follow-
up.Post-randomisationexclusionsoccurredin380(80%)
trials. The results reported by 270 of the 352 (77%)
superiority trials favoured the drug under investigation.
All of the 123 trials using equivalence or non-inferiority
methodstoinvestigateinterventionsreportedresultsthat
favoured their assumptions.
Conclusions Randomised controlled trials that report
using a modified intention to treat are increasingly being
published in the medical literature. The descriptions of
such an approach were ambiguous, and may cover any
type of descriptions for exclusion, such as missing data
and deviation from protocol. Explicit statements about
post-randomisation exclusions should replace the
ambiguous terminology of modified intention to treat.
INTRODUCTION
Missing data and deviations from protocol may drive
exclusions in randomised controlled trials. Excluding
patients after randomisation may introduce non-com-
parability of characteristics across treatment groups
and consequently lead to bias.
1-4
The intention to treat principle implies that patients
are analysed according to their original allocation,
regardless of the treatment they actually received.
Accordingly, withdrawals, losses to follow-up, and
crossovers are ignored in a strict intention to treat
analysis.
5
Several studies of randomised controlled trials pub-
lished in Medline and in top medical journals between
1993and1999
6-8reportedthatfewerthanhalfthetrials
usedtheintentiontotreatapproach,andinmanycases
the term was inappropriately described or participants
were improperly excluded.
6
Following revision of the CONSORT (consolidated
standards of reporting trials) statement,
9 a study
10 of
403 randomised controlled trials published during
2002in 10 medicaljournalsfound a higherproportion
of trials reporting use of intention to treat than before
the statement was revised. Among trials that reported
suchanapproach,however,only39%analysedallpar-
ticipants as they were initially randomised, and the
term “intention to treat” had many different inter
pretations.
10 The introduction of ambiguous terminol-
ogyintoanintentiontotreatanalysiscanbemisleading
and may encourage investigators to inappropriately
exclude participants after arbitrarily interpreting the
intention to treat principle. Trials using a modified
intention to treat approach are now appearing in the
medicalliteraturewithvaryingdescriptions.Forexam-
ple, a trial of an antifungal drug for the prevention of
infection in neutropenic patients described the modi-
fied intention to treat as allowing “all patients that
receivedatleastonedoseofstudydrug”tobeincluded
in analysis.
11 This approach described a case of devia-
tion from protocol which differs from that for cases of
missing data, with “a modified intent-to-treat principle
that included all randomised participants who had at
least one post-baseline measurement for the primary
outcome.”
12
In 2004 an updated CONSORT statement warned
thatusingthetermmodifiedintentiontotreatmaylead
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13 No appropri-
ate survey has been done on the extent to which mod-
ified intention to treat is relevant to modern
randomised controlled trials. We evaluated the inci-
dence and characteristics of randomised controlled
trials that reported using the modified intention to
treat approach, assessed the significance given to the
approach by authors, and discussed the implications
of the approach.
METHODS
We systematically searched PubMed, Embase, the
Cochrane central register of controlled trials, and ISI
Web of Knowledge and medical databases with full
text journal articles (Ovid, HighWire Press, Science-
Direct, Ingenta, Medscape, BioMed Central, Springer
and Wiley). To identify relevant randomised con-
trolled trials published in the English language from
the inception of each database platform until 31
December 2006, we used the search terms “modified
intention to treat”, “modified intent to treat”, and
“modified ITT”. We independently screened titles
and abstracts for potentially relevant studies and
selected them on the basis of reading the full text ver-
sions. One reviewer also screened the references of
reviews, systematic reviews, and meta-analyses to
identify potentially eligible studies. Articles were
includedonlyifthestudywasarandomisedcontrolled
trial with at least one analysis done using the modified
intention to treat approach. We excluded reviews,
meta-analyses, cost effectiveness studies, pharmacoki-
netic studies, abstracts, posters, editorials, commen-
taries,letters,andpublishedprotocolsofstudydesigns.
Study selection and data extraction
Before systematically extracting data from each trial,
wetestedthedataextractionmethodonarandomsam-
ple of 30 articles. Interpretation of different items was
discussed and classified. Subsequently, we indepen-
dently and in duplicate extracted the following data
using a standardised form: characteristics of the trial
(including the journal and year of publication), type
of primary and secondary outcomes reported, clinical
areaofinterest,interventionstudied,descriptionofthe
modified intention to treat approach, any potential
description of intention to treat, number of patients
includedin thestudy,P values,andthenumberofpar-
ticipantsexcludedfromtheanalysis.Wealsoextracted
information on sample size calculations, reporting of
equivalence or non-inferiority assumptions, reporting
of funding, and authors’ competing interests.
Incidence calculation
We expressed incidence as the ratio of all trials that
used the modified intention to treat approach over all
the published randomised controlled trials in each
year. To estimate the denominator for the incidence,
we identified randomised controlled trials published
each year from 1982 to 2006 by searching Medline
(via Ovid) and limiting the publication type to “rando-
mised controlled trial.” We also calculated the inci-
dence of trials in general medical journals using
modified intention to treat, where the denominator
was represented by the randomised controlled trials
published in the same general medical journals.
According to ISI Web of Knowledge, the highly cited
journals in general medicine are the New England Jour-
nal of Medicine, Lancet, JAMA, the Annals of Internal Med-
icine, and the BMJ.
Types of deviation from intention to treat
We retrievedthe typesand numberofdeviations from
a true intention to treat analysis that occurred in ana-
lyses reported as modified intention to treat and
accordingly classified the trials into six categories
(box). To avoid self interpretation, we categorised the
deviations by rigorously following the author’s
descriptions of modified intention to treat and inde-
pendently of other descriptions relating to exclusions
ofparticipants.Weindependentlyreviewedeacheligi-
ble trial for deviation. Differences were resolved by
discussion, and a consensus was reached.
Sinceexclusionsseemtobethedirectconsequenceof
themodifiedintentiontotreatdescription,wetestedthe
hypothesisthatthenumberofdeviationsfromintention
totreat waspositivelyassociated with the proportionof
occurrences of exclusions after randomisation.
Data analysis
We used the κ coefficient to determine the degree of
agreement between reviewers. Categorical variables
aredescribedbyfrequenciesandpercentages.Toeval-
uatethetrendovertimeintheproportionofpublished
randomised controlled trials that reported the use of a
modified intention to treat approach, we used a χ
2 test
forlineartrendwithonedegreeoffreedom.Weuseda
χ
2testandaKruskal-Wallistestwithonedegreeoffree-
dom to assess the hypothesisthat trials reporting more
Descriptions of deviations from intention to treat resulting in a “modified” intention to
treat
Treatment—treatment received by participants: “mITT [modified intention to treat]
population comprised all patients who were randomized to treatment and received at
leastone doseofstudy drug”
14; “mITT consisted of patients who received atleastsix doses
of study drug”
15
Baseline assessment—presenceofa baselineassessment: “mITT included patients withat
least one baseline observation”
16
Targetcondition—participantsrandomisedbutsubsequentlyexcludedfromtheanalysisif
found to lack the specific outcome or diagnosis at entry (either factor being difficult to
determine or only suspected at enrolment): “The mITT population consisted of those
patients who were randomly assigned to study treatment minus those who were not H
pylori positive”
17
Post-baseline assessment—presence of a post-baseline assessment: “mITT includes all
r a n d o m i z e dp a t i e n t sw h oh a v e...a tl e a s to n ep o s t - b a s e l i n em e a s u r e m e n t ”
18
Follow-up—lack of follow-up or participants failed to return for follow-up appointments:
“All participants who completed follow-up were analyzed as a part of the group to which
they were randomized. This was not a strict intent-to-treat analysis as some study
participants were lost to follow-up”
19
Other—trials that could not be placed into the other categories
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proportions of post-randomisation exclusions than
trials reporting one or no deviation.
Statistical analyses were carried out using Stata ver-
sion 8.2. We considered P values less than 0.05 to be
significant.
RESULTS
Thesearchgenerated1010records,containing475eli-
gible randomised controlled trials published in 198
journals indexed by Medline (fig 1).
Theestimatedincidenceoftrialsreportingtheuseof
modifiedintentiontotreatanalysisincreasedovertime
(P<0.001 for linear trend). At least 76 trials that
reported using a modified intention to treat approach
were published in highly cited medical journals: 35 in
JAMA, 17 in the New England Journal of Medicine,1 3i n
Lancet, 9 in the Annals of Internal Medicine, and 2 in the
BMJ.Infourjournals(JAMA,AnnalsofInternalMedicine,
Lancet,NewEnglandJournalofMedicine),theoverallinci-
denceofrandomisedcontrolledtrialsinwhichuseofa
modified intention to treat analysis was reported
increased from 0.3% in 1997 to 7.9% in 2006
(P<0.001 for linear trend; table 1).
In 12 trials (0.2%) the modified intention to treat
approach was used as a secondary analysis. In these
studies the primary analysis was by intention to treat
(11 trials) and by per protocol (one trial).
Of the 352 superiority trials, 270 (77%) reported sta-
tistically significant results that favoured the drug
under investigation. All of the 123 trials using equiva-
lence or non-inferiority methods to investigate inter-
ventions reported results that favoured their
assumptions.
A for profitagency funded418 (88%)of the trials. In
326 (68%) the authors explicitly declared financial ties
with industry. In 13 of the 26 trials for which funding
wasnotreported,atleastoneauthorwroteonbehalfof
a for profit agency. Table 2 describes the characteris-
tics of the 475 randomised controlled trials (full details
of the trials are available from the author).
Types of deviation in the modified intention to treat
description
Ofthe475trials,192(40%)reportedonetypeofdevia-
tion from the intention to treat approach, 189 (40%)
reported two, 67 (14%) reported three, five (1%)
reported four, and 22 (5%) did not report any type.
In 266 (56%) trials, the main criterion for exclusion
in the modified intention to treat analysis was treat-
ment related. Moreover, in 185 (70%) such trials the
treatment related approach was accompanied by at
least one additional type of deviation.
Post-baseline assessment related modified intention
to treat was described in 196 (41%) trials. In 160 (82%)
ofthesethe approachwasaccompaniedby atleast one
other type of deviation. In 118 (25%) trials, the exclu-
sionusedtojustifythecriteriaformodifiedintentionto
treat was the absence of a baseline assessment, and in
108(92%)trialsitwasassociatedwithatleastoneother
type of deviation.
Of the 108 (23%) trials describing a target condition
basedmodifiedintentiontotreat,78(72%)listedatleast
one additional type of deviation. Only 23 (5%) trials
based their criteria for modified intention to treat on
loss to follow-up, and 11 (48%) of these included one
or more type of deviation. Eighty two (17%) trials pre-
sented descriptions for a modified intention to treat
approach that did not fall into any of the defined cate-
gories (table 3). Figure 2 shows the overlap among the
four most common types of deviations.
Post-randomisation exclusions
Overall,380(80%)ofthetrialsreportedexclusionofat
least one participant owing to specifications for the
modified intention to treat. In the remaining 94 trials
Records identified (n=1010): 
  Ovid (n=581)
  Highwire (n=339)
  Science-Direct (n=258)
  Embase (n=126)
  PubMed (n=116)
  ISI Web of Knowledge (n=101)
  Cochrane central register of controlled trials (n=92)
  Springer (n=32)
  Ingenta (n=24)
  Medscape (n=20)
  Wiley (n=16)
  BioMed Central (n=11)
Randomised controlled trials identified (n=490)
Randomised controlled trials assessed (n=475)
Articles excluded on basis of title and abstract (n=420):
  Reviews (n=115)
  Reports (n=101) 
  Abstracts (n=89) 
  Correspondences (n=44)
  Commentaries (n=14) 
  Posters (n=30) 
  Other (n=27)
Articles excluded on basis of full text version (n=112):
  Non-randomised studies (n=54)
  Reviews or meta-analyses (n=58)
Additional trials identified from 58 reviews
or references in meta-analyses (n=12)
Trials excluded (n=15):
  Secondary publication (n=9)
  Modified intention to treat analysis not used (n=3)
  Cost effectiveness studies (n=3)
Fig 1 | Study screening process
Table 1 |Incidence of randomised controlled trials (RCTs) in which use of a modified intention
to treat (mITT) analysis was reported
Years of publication
No (%) of RCTs using mITT
Indexed in Medline Published in 4 highly cited general medical journals
1982-6 1/15 958 (0.006) —
1987-91 0/28 969 (0) —
1992-6 6/46 493 (0.013) —
1997-2001 71/56 427 (0.126) 9/1431 (0.6)
2002-6 378/72 178 (0.524) 65/1331 (4.9)
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the modified intention to treat approach. In one trial,
the modified intention to treat described a patient
crossover to another group. Of the trials reporting at
least one exclusion, the median percentage of exclu-
sions was 6% (interquartile range 2%-13%).
Statisticalanalysesdidnotindicateanypositiveasso-
ciation between the number of conditions provided in
the description of the modified intention to treat and
the proportion of participants excluded from the ana-
lysis (P=0.11).
DISCUSSION
The publication of randomised controlled trials in
which the use of the modified intention to treat
approach is reported has significantly increased in the
medical literature over time. Substantial variability
was observed in how the approach was defined. In at
least58%ofthetrialsthatexplicitlydescribedthemod-
ified intention to treat approach, more than one criter-
ion was reported. Therefore a predictable pattern of
modified intention to treat is difficult to identify.
Although an explanation for the emergence of use of
a modified intention to treat approach in the medical
literature remains unclear, this phenomenon may
reflectthedifficultythatinvestigatorsfacewhenmana-
ging missing data or deviations from protocol (present
in most trials) and at the same time avoid using the
intention to treat terminology.
Missing data and modified intention to treat
Missing data are a technically challenging problem in
randomised controlled trials because the outcome of
interest isunknown and the application ofa trueinten-
tion to treat is impractical.
2021 The literature reports
different types of missing data and different reasons
for data being missed.
22 Indeed, in our cohort of trials
different termswere used,such aspost-baseline assess-
ment, missing outcome, lost to follow-up, or “last
observation carried forward,” which imply the report-
ingof missingdata underthe descriptionofa modified
intention to treat approach. It is possible that authors
may want to define the modified intention to treat
approach as the use of intention to treat is impossible
in cases of missing data. However, the description of
modified intention to treat is not a good indicator for
Table 2 |Characteristics of randomised controlled trials
(n=475) in which use of modified intention to treat was
reported
Characteristics No (%)
Specialty
Infectious disease 136 (29)
Neurology or psychiatry 67 (14)
Rheumatology 43 (9)
Cardiology 41 (9)
Oncology or haematology 28 (6)
Gastroenterology 22 (5)
Gynaecology and obstetrics 17 (4)
Other 121 (25)
Type of comparison
Active drug v active drug 249 (52)
Active drug v placebo 200 (42)
Non-drug interventions* 22 (5)
Invasive procedures† 4 (1)
Type of intervention
Drugs for infectious disease 136 (29)
Antibiotics 94 (69)
Antifungals 24 (18)
Antivirals 12 (8)
Vaccine 6 (4)
Cyclo-oxygenase-2 inhibitors 45 (9)
Lipid lowering drugs 21 (4)
Monoclonal antibodies 19 (4)
Growth factors 14 (3)
Bisphosphonates 14 (3)
Other 226 (48)
Study design
Non-inferiority 67 (14)
Equivalence 56 (12)
Phase II 19 (4)
Quality of reporting
Flow chart 234 (49)
Adequate sequence generation 251 (53)
Adequate allocation concealment 124 (26)
Blinding:
Double blind 364 (77)
At least patient and investigator (or outcome
assessor) blinded
154
Single blind or open or not described 111 (23)
At least outcome assessor blinded 23
Reporting sample size 313 (66)
Sections reporting modified intention to treat
Title 0 (0)
Abstract 78 (16)
Introduction 4 (1)
Methods:
Statistical section 281 (59)
No statistical section 144 (30)
Results 215 (45)
Tables 164 (35)
Tables (only) 9 (2)
Discussion 38 (8)
Funding
For profit agency 418 (88)
Along with not for profit organisation 18
Characteristics No (%)
Not for profit organisation 31 (7)
Not reported 26 (5)
Report of competing interest
Reported employment with funding agency 201 (42)
Reported financial ties other than employment 125 (26)
No report of conflict of interest 125 (26)
Reported no potential conflict of interest 21 (4)
Support or employment from not for profit
organisation or government
3 (1)
*For example, psychological, diet.
†For example, stent implant, surgery.
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descriptions may be used but also because a missing
data related modified intention to treat often can be
associatedwithatleastoneothercondition.Inourana-
lysis,82%ofthe196randomisedcontrolledtrialsusing
a post-baseline assessment related modified intention
to treat listed one other type of deviation from the
approach.Thisassociationbetweentwotypesofdevia-
tion may generate some difficulties in understanding
which exclusions were related to a missing outcome.
Usually missing data cases are known as “available
cases” and the possible solution is either to omit the
missingdataortouseanimputationmethod,although
controversies remain.
2023
Deviation from protocol and modified intention to treat
A separate issue is the deviation from protocol when
participants are excluded. Several reasons are cited:
patients did not start treatment or did not receive the
entire treatment course, patients were ineligible
because they were mistakenly enrolled or because the
eligibilitycriteriaweretoobroad,patientswererando-
mised before information on eligibility was obtained
and therefore became ineligible, and patients died or
developed the outcome of interest before receiving
treatment.
624 All of these reasons were mentioned in
the descriptions of the modified intention to treat
reported in our survey. Indeed, possible deviations
from protocol such as those related to treatment, base-
line assessment, or target condition were associated
with at least one other type of deviation in 70-92% of
the cases. A substantial percentage of the missing data
intheseassociationswasrelatedtothismodifiedinten-
tion to treat approach, making any type of assumption
difficult.Inonetrial,themodifiedintentiontotreatwas
describedwiththreetypesofdeviationandsixpatients
were excluded: “modified intention to treat approach,
including all patients who received at least one dose of
randomised treatment, had a lipid measurement at
baseline, and at least one lipid measurement after the
start of treatment.”
18 However, it is not possible to
know which exclusions resulted from protocol
deviation(absenceofbaselineassessmentortreatment
not received) or a missing outcome (absence of a post-
baseline assessment). Furthermore, if one relies on the
strict description reported in the case of a deviation
from protocol, the outcome of interest of a participant
who is excluded should be known. In this situation, a
true intention to treat analysis could still be used.
Non-inferiority and equivalence assumption and modified
intention to treat
Innon-inferiority andequivalence trialsbothaninten-
tion to treat analysis and a per protocol analysis are
considered valid.
25 However, an intention to treat ana-
lysis is often conservative and the main concern is that
it may increase the chance of erroneously concluding
non-inferiority or equivalence. In our survey we iden-
tified 123 non-inferiority or equivalence trials that
reported on the use of modified intention to treat. In
these trials excluding participants who did not adhere
fully to the protocol can be justified. Exclusions may,
however, affect the balance between the randomised
groups and lead to bias if rates and reasons for exclu-
sion differ between groups.
2627
Treatment
related
(n=266)
2
(0%)
58
(12%)
36
(8%)
4
(1%)
11
(2%)
5
(1%)
8
(2%)
13
(3%)
48
(10%)
1
(0%)
3
(1%)
97
(20%)
32
(7%)
38
(8%)
53
(11%)
Baseline
assessment
(n=118)
Post
baseline
assessment
(n=196)
Target
related
(n=108)
Fig 2 | Number (percentage) of four most common types of
deviations from intention to treat. Each type of deviation
overlapped with at least one other type
Table 3 |Types and number of deviations from standard intention to treat in randomised controlled trials (n=470)* Values are numbers (percentages) of trials
unless specified otherwise
No of deviations
Type of deviation Median (interquartile range)
Treatment
related
Post baseline
assessment
Target
condition Follow-up
Baseline
assessment Other Total
No of
populations
Proportion of
exclusions
None 22/475 (5) 222 (50-624) 5 (3-8)
One 81 (42) 35 (18) 28 (15) 12 (6) 10 (5) 26 (14) 192/475 (40) 219 (97-467) 6 (2-13)
Two:
First deviation 121 (64) 5 (3) 10 (5) 2 (1) 48 (25) 3 (2)
189/475 (40) 387 (217-633) 6 (3-13)
Second deviation 102 (54) 51 (27) 5 (3) 9 (5) 22 (12)
Three:
First deviation: 59 (88) 1 (1) 1 (1) 6 (9)
67/475 (14) 296 (177-531) 8 (2-16) Second deviation 8 (12) 10 (15) 2 (3) 42 (63) 5 (7)
Third deviation 42 (63) 4 (6) 1 (1) 20 (30)
*Five trials reported four types of deviation: median sample 145 (interquartile range 142-409); median proportion of exclusions 36 (2-40).
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Investigatorssometimeswereinconsistentinhowthey
described the modified intention to treat approach—
the same authors gave different descriptions in two
publications, even though the treatment under investi-
gationandthehypothesisbeingtestedwerethesamein
both studies.
1128 The exclusion rationale does not
necessarily reflect the description. In one trial, investi-
gators described a treatment related modified inten-
tion to treat approach and excluded three patients
because they did not start treatment after
randomisation,
29 whereas the real reasons for these
exclusions were stroke in one patient and withdrawal
in the others. In another study it was unclear why the
authors described a modified intention to treat (“all
patients that took at least one dose of drug”) that they
considered equivalent to intention to treat. In this
study, all of the enrolled patients satisfied the criteria
for a modified intention to treat and no patient was
excluded from the analysis, indicating a true intention
to treat approach.
30 In a study testing a monoclonal
antibody, the authors justified their treatment related
modified intention to treat as a “standard practice in
drug registration studies seeking to identify treatment
effects,” ignoring the essential methodology of carry-
ing out randomised controlled trials.
31
Implications
The unpredictable and multiple deviations in the
descriptions of modified intention to treat approaches
may result in authors arbitrarily describing the
approach and carrying out exclusions. For example,
although in most cases of the descriptions of treatment
related modified intention to treat the excluded
patients were those who never received a drug, in
12% of these 266 trials the required amount of treat-
ment for patients to be included ranged from two
daystosixmonths.Thesedifferentchoicesaredifficult
to interpret.
Excluding participants is incompatible with inten-
tion to treat and may bias results. In comparison with
the as treated or per protocol analysis, the intention to
treat analysis is more conservative.
132-35 Even a few
exclusions may produce misleading results or become
relevantwhentrialsare consideredformeta-analyses.
3
A survey using individual patient data from 14 meta-
analyses on cancer found an overestimation of the
treatment effect when exclusions occurred.
3 However,
a meta-epidemiological study that used data from 14
meta-analysesonosteoarthritisreportedthattheextent
and direction of bias due to post-randomisation exclu-
sions can be unpredictable.
4
In our sample of studies, we cannot know if the
results might have been conservative if exclusions
were avoided. However, 77% of the 352 superiority
trials reported results that favoured the experimental
drug. The prevalence of these trials with significant
results was high and unexpected. The results might
notreflecttruedifferences,becausethenullhypothesis
ofnodifferenceislikelytobetrue.
36Importantly,there
is a tendency to report statistically significant results in
published trials.
36 This preponderance can be a conse-
quence of many outcomes, and authors may selec-
tively report secondary analysis depending on the P
value.
37-39 One study reported that the method
described for handling protocol deviation was differ-
entfromthatdescribedintheprotocolin19of43trials
examined.
40 We were unable to investigate any possi-
ble discrepancy between the description of the modi-
fied intention to treat in the protocol and the one
reported in the respective published trial. The erratic
and multiple conditions under which modified inten-
tion to treat is reported may induce arbitrary multiple
secondary analysis driven by the “level” of exclusion.
Strengths and limitations of the study
Ourcomprehensivesearchof12databasesyielded475
randomised controlled trials. The abstracts did not
always report on modified intention to treat; terminol-
ogy related to a modified intention to treat approach
waspresentinonly16%(table 2)andthereforeeligible
trials would be missed by searches of general data-
bases, such as Medline or Embase. Most of the
includedarticleswerefromdatabasesthathostelectro-
nic journals. Our study may have underestimated the
incidence of trials using the modified intention to treat
approach because many journals are not hosted by
databases that provide full text articles. Additionally,
trials labelled as using the intention to treat approach
when they used the modified intention to treat
approach owing to the type of deviation present in
the description of the analysis may have escaped our
search. Therefore, this study may have further under-
estimated the incidence of trials using the modified
intention to treat approach.
We included trials that reported the use of modified
intention to treat analyses only. This criterion limited
our ability to compare funding, conflicts of interest,
methodological quality, and post-randomisation
exclusions between trials that report using standard
intention to treat analyses and those that report using
modified intention to treat. Further studies are neces-
sary to address these issues.
Conclusion
Published trials have deficiencies in their design.
41
However, reports indicate that journal endorsement
of the CONSORT statement is associated with
improvementinthequalityofreportingofrandomised
controlled trials.
4243 In this scenario, the increasing
appearance of randomised controlled trials that report
use of the modified intention to treat approach can be
considered a shortcoming in the quality of reporting.
The misuse of the intention to treat definition or the
introduction of the modified intention to treat term
cannot overcome problems related to missing data or
protocoldeviations.Inconsistentandmultipledescrip-
tions of the modified intention to treat approach may
cause failure to achieve the standard intention to treat
principle, which is the best method that preserves
RESEARCH
page 6 of 8 BMJ | ONLINE FIRST | bmj.comrandomisation. We recommend the intention to treat
approach as the method of choice for analysis in trials
investigating the superiority of an intervention.
Authors should provide complete information on
post-randomisation exclusions if thereare appropriate
reasons to exclude participants.
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